Compare Jones Lang LaSalle Inc (JLL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs GeneDx Holdings Corp — how do they compare? Jones Lang LaSalle Inc trades at $361.84 (market cap $16.72B), while GeneDx Holdings Corp trades at $82.11 (market cap $2.44B). The key difference: Jones Lang LaSalle Inc is far larger — about 6.9× GeneDx Holdings Corp's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| JLL | WGS | |
|---|---|---|
Market Cap | $16.72B | $2.44B |
Sector | Real Estate | Technology |
52-Week High | $373.24 | $167.51 |
52-Week Low | $280.16 | $34.51 |
Enterprise Value | $19.48B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $362.81, up 1.53% today, near its 52-week high. The stock exhibits strong technical momentum with a bullish moving average crossover and is supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Revenue growth accelerated to $26.12 billion in 2025, with net income margin improving to 3.64%. Analyst sentiment is positive with a 54.55% buy rating and a consensus price target of $391.50, suggesting further upside potential from current levels.
The outlook for JLL is favorable, driven by robust earnings performance and solid cash flow generation. Key opportunities include continued growth in leasing and capital markets, while risks involve economic sensitivity and competitive pressures in real estate services. The stock's valuation at a P/E of 17.43 and P/S of 0.63 appears reasonable relative to growth prospects.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
